Journal
DRUG DELIVERY
Volume 30, Issue 1, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2023.2179127
Keywords
Valsartan; solid lipid nanoparticles; stroke; factorial design; transmission electron microscopy; photon imaging
Categories
Ask authors/readers for more resources
The research aims to utilize solid lipid nanoparticles (SLNs) to transport valsartan across the blood-brain barrier (BBB) and mitigate the adverse effects of stroke. The optimized SLN formula showed sustained drug release, reducing the dose frequency and improving patient compliance. This method holds promise for delivering valsartan to the brain and alleviating the negative consequences of stroke.
The brain is a vital organ that is protected from the general circulation and is distinguished by the presence of a relatively impermeable blood brain barrier (BBB). Blood brain barrier prevents the entry of foreign molecules. The current research aims to transport valsartan (Val) across BBB utilizing solid lipid nanoparticles (SLNs) approach to mitigate the adverse effects of stroke. Using a 3(2)-factorial design, we could investigate and optimize the effect of several variables in order to improve brain permeability of valsartan in a target-specific and sustained-release manner, which led to alleviation of ischemia-induced brain damage. The impact of each of the following independent variables was investigated: lipid concentration (% w/v), surfactant concentration (% w/v), and homogenization speed (RPM) on particle size, zeta potential (ZP), entrapment efficiency (EE) %, and cumulative drug release percentage (CDR) %. TEM images revealed a spherical form of the optimized nanoparticles, with particle size (215.76 +/- 7.63 nm), PDI (0.311 +/- 0.02), ZP (-15.26 +/- 0.58 mV), EE (59.45 +/- 0.88%), and CDR (87.59 +/- 1.67%) for 72 hours. SLNs formulations showed sustained drug release, which could effectively reduce the dose frequency and improve patient compliance. DSC and X-ray emphasize that Val was encapsulated in the amorphous form. The in-vivo results revealed that the optimized formula successfully delivered Val to the brain through intranasal rout as compared to a pure Val solution and evidenced by the photon imaging and florescence intensity quantification. In a conclusion, the optimized SLN formula (F9) could be a promising therapy for delivering Val to brain, alleviating the negative consequences associated with stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available